Stock Price
2.17
Daily Change
-0.18 -7.66%
Monthly
-3.98%
Yearly
69.53%
Q2 Forecast
2.13

Galectin Therapeutics reported $-7.42M in EBITDA for its fiscal quarter ending in December of 2021.





Ebitda Change Date
AbbVie USD 5.37B 1.85B Dec/2025
Bristol-Myers Squibb USD 2.88B 1.36B Dec/2025
Galectin Therapeutics USD -7.42M 819K Dec/2021
Gilead Sciences USD 3.02B 1.01B Dec/2025
Immunic USD -22.78M 753K Jun/2024
Incyte USD 367.97M 46.53M Mar/2026
Merck USD 6.3B 2.09B Dec/2025